Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Presented By
Prof. Byoung Chul Cho, Yonsei Cancer Center Seoul, South Korea
Conference
ELCC 2022
Trial
Phase 1/2, ALKA-372-001, STARTRK-1, STARTRK-2
Doi
https://doi.org/10.55788/5884e488
In an integrated analysis of 3 trials, entrectinib was associated with deep and durable responses in patients with NTRK fusion-positive (-fp) non-small cell lung cancer (NSCLC), including those with baseline CNS metastases. Fusions involving the NTRK gene family lead to the expression of chimeric rearrangements in tropomyosin receptor kinases (TRKs) with constitutively active kinase function. NTRK gene fusions act as oncogenic drivers and are potential therapeutic targets across a broad range of tumour types, including NSCLC [1]. Entrectinib is a potent inhibitor of TRK proteins that is specifically designed to have systemic activity and crosses the blood-brain barrier. Entrectinib has shown strong efficacy in patients with NTRK-fp solid tumours in the phase 1/2 ALKA-372-001 (EudraCT 2012-000148-88), STARTRK-1 (NCT02097810), and ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on